Evidence map›Paper›PMID 37507528›Full record

ArticleWorld journal of urology2023

Post-chemotherapy robot-assisted retroperitoneal lymph node dissection for metastatic germ cell tumors: safety and perioperative outcomes.

Nicolas Branger, Franck Bladou, Gregory Verhoest, Sophie Knipper, Grégoire Robert, Jean-Christophe Bernhard, Jean-Baptiste Beauval, Abderrahmane Khaddad, Anne Mauger De Varennes, Aude Fléchon and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Nicolas BrangerDepartment of Urology, Institut Paoli Calmettes Cancer Center, Marseille, France. brangern@ipc.unicancer.fr.ORCID http://orcid.org/0000-0001-7024-7322
Franck BladouDepartment of Urology, CHU Bordeaux, Bordeaux, France.
Gregory VerhoestDepartment of Urology, CHU Rennes, Rennes, France.
Sophie KnipperDepartment of Urology, Institut Paoli Calmettes Cancer Center, Marseille, France.
Grégoire RobertDepartment of Urology, CHU Bordeaux, Bordeaux, France.
Jean-Christophe BernhardDepartment of Urology, CHU Bordeaux, Bordeaux, France.
Jean-Baptiste BeauvalDepartment of Urology, CHU Toulouse, Toulouse, France.
Abderrahmane KhaddadDepartment of Urology, CHU Bordeaux, Bordeaux, France.
Anne Mauger De VarennesDepartment of Urology, CHU Rennes, Rennes, France.
Aude FléchonDepartment of Oncology, Centre Léon Bérard, Lyon, France.
Jochen WalzDepartment of Urology, Institut Paoli Calmettes Cancer Center, Marseille, France.
Anne-Sophie BageotDepartment of Urology, CHU Toulouse, Toulouse, France.
Nicolas DoumercDepartment of Urology, CHU Toulouse, Toulouse, France.
Morgan RouprêtDepartment of Urology, La Pitié Salpêtrière, Paris, France.
Thibault MurezDepartment of Urology, CHU Montpellier, Montpellier, France.
French AFU Testicular Cancer Committee
Centre Hospitalier Universitaire de Bordeaux · FRCentre Hospitalier Universitaire de Toulouse · FRInstitut Paoli-Calmettes · FRCentre Hospitalier Universitaire de Rennes · FRCentre Hospitalier Universitaire de Montpellier · FRCentre Léon Bérard · FRSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the feasibility, safety, and early oncologic outcomes after post-chemotherapy robot-assisted retroperitoneal lymph node dissection (PC-RARPLND) for metastatic germ cell tumors (mGCT).

methodsWe retrospectively analyzed patients from four tertiary centers who underwent PC-RARPLND for mGCT, from 2011 to 2021. Previous treatment of mGCT, intraoperative and postoperative complications, and early oncologic outcomes were assessed.

resultsOverall, 66 patients were included. The majority of patients had non-seminoma mTGCT (89%). Median size of retroperitoneal lymph node (RLN) before surgery was 26 mm. Templates of PC-RARPLND were left modified, right modified, and full bilateral in 56%, 27%, and 14%, respectively. Median estimated blood loss and length of stay were 50 mL [50-150] and 2 [1-3] days. Four patients (6.1%) had a vascular injury, only one with significant blood loss and conversion to open surgery (OS). Two other patients had a conversion to OS for difficulty of dissection. No patient had transfusion, most frequent complications were ileus (10.6%) and symptomatic lymphorrea (7.6%) and no complications grade IIIb or more occurred. With a median follow-up of 16 months, two patients had a relapse, all outside of the surgical template (one in the retrocrural space with reascending markers, one in lungs).

conclusionPC-RARPLND is a challenging surgery. In expert centers and for selected patients, it seemed safe and feasible, with a low morbidity. Further prospective evaluation of this procedure and long-term oncologic results are needed.

Indexed as

Neoplasms, Germ Cell and EmbryonalRoboticsTesticular NeoplasmsHumansLymphatic MetastasisLymph Node ExcisionLymph NodesMaleRetroperitoneal SpaceRetrospective StudiesMinimally invasive surgeryPost-chemotherapy robot-assisted retroperitoneal lymph node dissectionRobot-assisted retroperitoneal lymph node dissectionTesticular cancerTesticular germ cell tumor

Identifiers

PMID37507528
OpenAlexW4385334737

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.